UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                          Washington, D. C. 20549

                                 FORM 10-Q

     (Mark One)
(X)   Quarterly Report Under Section 13 or 15(D) of The Securities Exchange
       Act of 1934 For Quarter Ended June 30, 2003

                       OR

( )   Transition Report Pursuant to Section 13 or 15(d) of The  Securities
       Exchange Act of 1934


                        Commission File Number 0-275


                             Allen Organ Company
          (Exact name of registrant as specified in its charter)



     Pennsylvania                       23-1263194
  (State of Incorporation)      (I.R.S. Employer Identification No.)



  150 Locust Street, P. O. Box 36, Macungie, Pennsylvania      18062-0036
  (Address of principal executive offices)                     (Zip Code)



Registrant's telephone number, including area code           610-966-2200


Indicate  by  check mark whether the registrant (1) has filed  all  reports
required to be filed by Section 13 or 15(d) of the Securities Exchange  Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject  to
such filing requirements for the past 90 days.

                              Yes  X   No

Indicate by check mark whether the registrant is an accelerated filer as
defined in Rule 12b-2 of the Exchange Act.
                              Yes      No  X

Number of shares outstanding of each of the issuer's classes of common
stock, as of August 13, 2003:

                    Class A - Voting          83,864 shares
                    Class B - Non-voting   1,072,696 shares
<PAGE>
                            ALLEN ORGAN COMPANY

                                   INDEX


Part I  Financial Information

   Item 1.Financial Statements
          Consolidated Condensed Statements of Income for the three and
           six months ended June 30, 2003 and 2002

          Consolidated Condensed Balance Sheets at June 30, 2003 and
           December 31, 2002

          Consolidated Condensed Statements of Cash Flows for the three
           and six months ended June 30, 2003 and 2002

          Notes to Consolidated Condensed Financial Statements

   Item 2.Management's Discussion and Analysis of Financial Condition
           and Results of Operations

   Item 3.Quantitative and Qualitative Disclosures About Market Risk

   Item 4.Controls and Procedures

Part II    Other Information

   Item 4.Submission of Matters to a Vote of Security Holders

   Item 6.Exhibits and Reports on Form 8-K

Signatures

Exhibits
<PAGE>
PART I  FINANCIAL INFORMATION
   ITEM 1.FINANCIAL STATEMENTS

                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
                CONSOLIDATED CONDENSED STATEMENTS OF INCOME
                                (Unaudited)

                        For the 3 Months Ended:     For the 6 Months Ended:
                        6/30/2003     6/30/2002     6/30/2003     6/30/2002

Net Sales              $12,725,880   $17,403,733   $26,600,344   $33,381,221

Cost and Expenses
 Costs of sales          7,503,053    10,245,150    16,102,563    19,594,210
 Selling, general and
  administrative         3,641,661     3,747,172     7,109,627     7,256,805
 Research and
  development            1,920,082     2,035,534     3,850,577     4,002,651
   Total Costs and
    Expenses            13,064,796    16,027,856    27,062,767    30,853,666


(Loss) Income from
 Operations               (338,916)    1,375,877      (462,423)    2,527,555

Investment and Other
 Income                     79,018       103,757       182,717       245,618

(Loss) Income Before
  Taxes                   (259,898)    1,479,634      (279,706)    2,773,173


Income Tax Provision
 (Benefit)                (110,000)      470,000      (110,000)      832,000


Net (Loss) Income        $(149,898)   $1,009,634     $(169,706)   $1,941,173


Basic and Diluted
 (Loss) Earnings
  Per Share               $  (0.13)      $  0.86        $(0.15)       $ 1.66


Weighted Average Shares
 Used in Per Share
 Calculation             1,163,662     1,170,321     1,163,662     1,170,321


Dividends Per Share -
 Cash                       $ 0.14        $ 0.14        $ 0.28        $ 0.28


Total Comprehensive
 (Loss) Income           $(143,796)    $1,054,941    $(166,118)   $1,977,174

                           See accompanying notes.
<PAGE>
                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
                   CONSOLIDATED CONDENSED BALANCE SHEETS

                                                June 30, 2003  Dec 31, 2002
         ASSETS                                   (Unaudited)    (Audited)
Current Assets
  Cash                                            $5,679,470    $4,515,189
  Investments Including Accrued Interest          17,299,940    17,176,750
  Accounts Receivable, net of reserves of
   $565,203 and $502,209, respectively             5,952,896    12,184,564
  Inventories:
     Raw Materials                                 5,067,984     5,451,664
     Work in Process                               6,081,279     5,707,215
     Finished Goods                                4,300,891     5,064,803
      Total Inventories                           15,450,154    16,223,682
  Prepaid Income Taxes                                79,825       161,071
  Prepaid Expenses                                   572,279       318,943
  Deferred Income Taxes                            1,994,713     1,992,694
     Total Current Assets                         47,029,277    52,572,893
Property, Plant and Equipment                     27,527,301    27,328,631
  Less Accumulated Depreciation                  (17,193,732)  (16,471,137)
   Net Property, Plant and Equipment              10,333,569    10,857,494
Other Assets
  Note Receivable from Related Party               2,397,291     2,397,291
  Cash Value of Life Insurance                     2,273,163     2,273,163
  Deferred Income Taxes                            3,422,448     3,422,448
  Intangible Assets, net                           1,365,932     1,628,964
  Goodwill, net                                      194,523       194,523
  Other Assets                                        15,000        16,092
   Total Other Assets                              9,668,357     9,932,481
    Total Assets                                 $67,031,203   $73,362,868

   LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES
Current Liabilities
  Accounts Payable                                 $ 763,714    $5,688,967
  Other Accrued Expenses                           2,654,736     2,638,258
  Customer Deposits                                2,490,175     2,693,980
   Total Current Liabilities                       5,908,625    11,021,205

Noncurrent Liabilities
  Deferred and Other Noncurrent Liabilities        1,272,417     1,028,785
  Accrued Pension Costs                            4,534,663     5,006,546
   Total Noncurrent Liabilities                    5,807,080     6,035,331
    Total Liabilities                             11,715,705    17,056,536

STOCKHOLDERS' EQUITY
  Common Stock   2003              2002
     Class A   127,232 shares;   127,232 shares      127,232       127,232
     Class B 1,410,761 shares; 1,410,761 shares    1,410,761     1,410,761
  Capital in Excess of Par Value                  12,961,610    12,961,610
  Retained Earnings
     Balance, Beginning                           57,267,763    55,237,713
     Net (Loss) Income                              (169,706)    2,685,357
     Dividends - Cash 2003 and 2002                 (325,727)     (655,307)
     Balance, End                                 56,772,330    57,267,763
  Accumulated Other Comprehensive Loss            (3,464,051)   (3,460,463)
   Sub-total                                      67,807,882    68,306,903
  Treasury Stock
   2003- 43,368 Class A shares
        338,065 Class B shares                   (12,492,384)        --
   2002- 43,368 Class A shares
        324,565 Class B shares                         --      (12,000,571)
    Total Stockholders' Equity                    55,315,498    56,306,332
     Total Liabilities and Stockholders' Equity  $67,031,203   $73,362,868

                          See accompanying notes.
<PAGE>
                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
              CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                                (Unaudited)

                                For the 3 Months Ended: For the 6 Months Ended:
                                 6/30/2003   6/30/2002   6/30/2003   6/30/2002
CASH FLOWS FROM OPERATING
ACTIVITIES
 Net(loss) income                $(149,898) $1,009,634   $(169,706) $1,941,173
 Adjustments to reconcile net
 (loss) income to net cash
  provided by operating activities
   Depreciation and amortization   614,720     703,509   1,220,789   1,419,455
   Deferred income tax benefits       (936)     18,347      (2,019)     19,031
 Change in assets and liabilities
   Accounts receivable           2,239,453    (843,689)  6,231,668     251,500
   Inventories                     506,179   1,021,806     773,528     489,000
   Income taxes prepaid and
    receivable                     (79,825)   (525,598)     81,246    (278,778)
   Prepaid expenses                 71,958      42,525    (253,336)   (163,993)
   Other assets                       --          --         1,092        --
   Accounts payable               (560,659)    (10,481) (4,925,253)   (165,805)
   Accrued taxes on income         (33,175)       --          --          --
   Accrued expenses                 33,213     194,079      16,478     424,997
   Customer deposits                55,083     176,691    (203,805)     69,239
   Accrued pension costs          (721,882)    293,486    (471,883)    173,443
   Deferred and other noncurrent
    liabilities                    164,567      12,465     243,632      92,719
     Net Cash Provided by
      Operating Activities       2,138,798   2,092,774   2,542,431   4,271,981

CASH FLOW FROM INVESTING
 ACTIVITIES
   Increase in note receivable        --          --          --      (400,184)
   Net additions to plant and
    equipment                     (179,117)   (666,082)   (368,662)   (947,250)
   Additions to goodwill and
    intangible assets                6,886        --      (187,770)     (2,780)
   Net sale of short term
    investments                    (66,500)  1,892,322    (126,778)  1,795,698
     Net Cash (Used In) Provided
      by Investing Activities     (238,731)  1,226,240    (683,210)    445,484

CASH FLOWS FROM FINANCING
 ACTIVITIES
   Proceeds from sales of
    subsidiary stock                 1,350        --       122,600       2,040
   Reacquired Class B common
    shares                        (491,813)       --      (491,813)       --
   Dividends paid in cash         (161,919)   (163,845)   (325,727)   (327,690)
     Net Cash Used In Financing
      Activities                  (652,382)   (163,845)   (694,940)   (325,650)

NET INCREASE IN CASH             1,247,685   3,155,169   1,164,281   4,391,815

CASH, BEGINNING                  4,431,785   5,686,644   4,515,189   4,449,998

CASH, ENDING                    $5,679,470  $8,841,813  $5,679,470  $8,841,813


            SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION
Cash paid (refunded) for:
   Income Taxes                 $     --    $  995,598  $ (194,246) $1,110,778
   Interest                     $     --    $     --    $     --    $     --

                          See accompanying notes.
<PAGE>
                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
           NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

1. Interim Financial Statements
   The  results of operations for the interim periods shown in this  report
   are  not necessarily indicative of results to be expected for the fiscal
   year.   In  the opinion of management, the information contained  herein
   reflects  all  adjustments necessary to make the results  of  operations
   for  the interim periods a fair statement of such operations.  All  such
   adjustments are of a normal recurring nature.

   Certain notes and other information have been condensed or omitted  from
   the  interim financial statements presented in the Quarterly  Report  on
   Form  10-Q.   Therefore, these financial statements should  be  read  in
   conjunction with the Company's 2002 Annual Report on Form 10-K.

2. Stock-Based Compensation
   The  Company accounts for its stock-based compensation plans  using  the
   accounting  prescribed by Accounting Principles Board  Opinion  No.  25,
   Accounting  for  Stock Issued to Employees.  Since the  Company  is  not
   required   to   adopt  the  fair  value  based  recognition   provisions
   prescribed  under Statement of Financial Accounting Standards  No.  123,
   as  amended by SFAS No. 148, Accounting for Stock-Based Compensation, it
   has  elected only to comply with the disclosure requirements  set  forth
   in the Statements.

   Had  compensation  cost  been determined on  the  basis  of  fair  value
   pursuant to SFAS No. 123, as amended by SFAS No. 148, net (loss)  income
   and earnings per share would have been decreased as follows:

                             Three Months Ended         Six Months Ended
                                  June 30,                  June 30,
                              2003         2002         2003         2002

     Net (loss) income
      As Reported          $(149,898)   $1,009,634   $ (169,706)  $1,941,173
     Total stock-based
     employee compensation
     benefit (expense)
     determined under fair
     value based method for
     all awards, net of
     related tax effects      11,790       (17,343)      23,580      (34,687)
      Pro forma            $(138,108)     $992,291   $ (146,126)  $1,906,486

    (Loss) earnings per share
      As reported          $   (0.13)     $   0.86   $    (0.15)  $     1.66
      Pro forma            $   (0.12)     $   0.85   $    (0.13)  $     1.63



        The  fair  value of each option granted is estimated on  the  grant
     date  using  the  Black-Scholes option pricing model.   The  following
     assumptions were made in estimating the fair value of options  granted
     under the Allen Organ Company stock option plan:

          Assumptions
           Dividend yield                   1.40%
           Risk-free interest rate          2.50%
           Expected life                  7 years
           Expected volatility                10%

3. Warranty Costs
   The  Company  provides  a  warranty covering manufacturing  defects  for
   certain  of  its  products for varying lengths of time.   The  Company's
   policy is to accrue the estimated cost of warranty coverage at the  time
   the  sale is recorded.  The activity in the warranty accrual during  the
   six months ended June 30, 2003 is summarized as follows:

       Accrual at January 1, 2003                    $ 300,000
       Additions charged to  warranty expense           60,886
       Claims paid and charged against the accrual     (30,886)
       Accrual at June 30, 2003                      $ 330,000

4. Earnings Per Share
   Outstanding  stock options were not included in computing  earnings  per
   share  because  their effect was antidilutive as the exercise  price  of
   the  options  was  above  the average trading price  of  the  underlying
   stock.  Options excluded were 12,000 for the three and six months  ended
   June 30, 2003 at a weighted average exercise price of $39.00 per share.

5. Subsequent Event
   On  July  24,  2003,  the Company's subsidiary, Eastern  Research,  Inc.
   (ERI),  purchased the assets of Avail Networks, Inc. (Avail) in exchange
   for  $200,000  in cash and contingent payments based on  future  revenue
   related to Avail products during the next 30 months.

   Avail's   intelligent  last-mile  broadband  solutions  enable   service
   providers  worldwide  to  deliver  more revenue-generating  services  to
   their  enterprise  customers  from a single  customer  located  platform
   across  metro fiber, traditional wireline and wireless access  networks.
   Avail's  flagship FronteraT products deliver multiple services  to  end-
   user sites in a variety of subscriber locations and configurations.

   The  acquisition  of  Avail reinforces ERI's commitment  to  the  access
   network  market.   With  the addition of the Frontera  products  to  its
   existing  product offerings, ERI is positioned as a supplier of  network
   access  solutions for next-generation convergence applications, such  as
   integrated data, voice and video over single broadband connections.   In
   addition,  this  acquisition gives ERI access to  Avail's  advanced  ATM
   (Asynchronous Transmission Mode) technology.

   Avail's  sales  prior to the acquisition date have been  minimal.   With
   the  Frontera products ready for production, ERI will introduce them  to
   their  established  customer base.  Due to lengthy sales  cycles,  these
   products are not expected to add significant revenues in the near-term.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND
RESULTS OF OPERATIONS.

Liquidity and Capital Resources:
    Cash flows from operating activities during the three months ended June
30,  2003 were approximately equal to the same period in 2002 and decreased
during  the six months ended June 30, 2003 primarily due to lower operating
income in the Musical Instruments and Data Communications segments.

Results of Operations:

Sales and Operating Income
                                For the 3 Months           For the 6 Months
                                     Ended:                   Ended:
                            6/30/2003    6/30/2002    6/30/2003     6/30/2002
  Net Sales to
   Unaffiliated Customers
     Musical Instruments  $ 4,819,569   $ 6,616,642  $10,190,294   $12,922,843
     Data Communications    6,709,970     8,858,220   14,041,953    17,524,514
     Electronic Assemblies    752,751     1,510,961    1,529,144     2,096,816
     Audio Equipment          443,590       417,910      838,953       837,048
       Total              $12,725,880   $17,403,733  $26,600,344   $33,381,221

  Intersegment Sales
     Musical Instruments  $   254,398   $    92,737  $   413,709   $   165,146
     Data Communications         --            --           --            --
     Electronic Assemblies       --           6,616         --          82,477
     Audio Equipment           23,988        15,837       36,039        58,234
       Total              $   278,386   $   115,190  $   449,748   $   305,857

  Income (Loss) from Operations
     Musical Instruments  $  (423,300)  $   821,967  $  (514,389)  $ 1,645,877
     Data Communications      301,563       772,376      553,259     1,472,228
     Electronic Assemblies   (174,446)     (110,660)    (409,456)     (348,462)
     Audio Equipment          (42,733)     (107,806)     (91,837)     (242,088)
       Total              $  (338,916)  $ 1,375,877  $  (462,423)  $ 2,527,555

Musical Instruments Segment
    Sales decreased $1,797,073 and $2,732,549, respectively, for the  three
and  six  months ended June 30, 2003 when compared to the same  periods  in
2002  due  to lower order volume, which management believes is attributable
to  the overall economic slowdown.  The first six months of 2002 sales were
also higher due to the shipment of organs from the order backlog, which was
higher at the beginning of 2002.

    The gross profit percentage decreased to 19.1% and 20.8%, respectively,
in  the  three  and  six months ended June 30, 2003 from 33.7%  and  33.3%,
respectively,  in  the same periods in 2002.  These decreases  are  due  to
lower  sales  volume over which to absorb fixed costs and higher  operating
costs  including employee pension expense.  The Company has taken steps  to
reduce  its operating costs at the Macungie, PA plant, including reductions
in personnel.

    Selling, general and administrative, research and development  expenses
increased slightly during the three and six months ended June 30, 2003 when
compared  to  the  same  periods in 2002 due primarily  to  higher  pension
expense.

Data Communications Segment
    Sales decreased $2,148,250 and $3,482,561, respectively, for the  three
and  six  months ended June 30, 2003 when compared to the same  periods  in
2002.  This decrease is attributable to the continued economic weakness  in
the  data  communications market and the timing of  completing  sales  with
larger customers.

    Gross profit margins increased to 62.3% and 58.4%, respectively, during
the  three and six months ended June 30, 2003 from 54.5% and 53.6%.   These
increases  are  primarily related to $1,400,000 of  revenue  recognized  on
product  software development for a customer during the second  quarter  of
2003.   Excluding this item, gross margins were approximately equal to  the
same periods in 2002.

    Sales & marketing and general & administrative expenditures during  the
three  and six months ended June 30, 2003 were approximately equal  to  the
same periods in 2002.

   Research and development expenses decreased approximately $181,000 (11%)
and $312,000 (9%), respectively, during the three and six months ended June
30,  2003  when  compared to the same periods in 2002.  The  2002  expenses
included  product  development  costs related  to  the  DNX-1u,  which  was
introduced in mid-2002.  Research and development expenses will increase in
future periods due to the acquisition of Avail Networks discussed in Note 5
above.   In connection with this acquisition, ERI will employ approximately
10 additional development people.

     Future   sales   visibility  remains  limited  throughout   the   data
communications market that ERI serves with certain companies that buy  Data
Communications  equipment  continuing to lower  their  capital  expenditure
spending   for  such  equipment.   These  factors,  along  with   continued
uncertainty  in  completing  sales to larger accounts,  create  significant
uncertainty for operating results in future quarters.

Electronic Assemblies Segment
    Sales decreased $758,210 and $567,672, respectively, for the three  and
six  months ended June 30, 2003, when compared to the same periods in 2002,
due  to  lower  order  volume  from  the Company's  contract  manufacturing
customers  who  were affected by the economic slowdown.   This  segment  is
focused  on  diversifying its customer base and it has been  successful  in
obtaining  new customers.  The potential sales significance  of  these  new
accounts cannot be determined at this time.

    The gross profit margin was a loss of approximately $(86,000) (11%) and
$(234,000) (15%), respectively, for the three and six months ended June 30,
2003,  compared  to a loss of approximately $(24,000) (2%)  and  $(178,000)
(8%)  during the same periods in 2002.  These losses are primarily  due  to
lower sales volume over which to absorb fixed costs.  Selling, general  and
administrative expenses during the three and six months ended June 30, 2003
were  approximately  equal to the same periods in 2002.   The  Company  has
taken  steps  to  reduce  its operating costs at  the  Macungie,  PA  plant
including reductions in personnel.

Audio Equipment Segment
    Sales  for  the  three  and six months ended June  30,  2003  increased
slightly  when compared to the same periods in 2002.  Legacy Audio  remains
focused  on  developing a quality independent dealer network  of  high  end
audio video stores and custom installers.

    Gross  profit margins were 34% and 36%, respectively, in the three  and
six  months  ended June 30, 2003, as compared to 21% and 25%  in  the  same
periods  in  2002, primarily due to lower operating costs  related  to  the
closure  of  the Springfield, IL plant and consolidation of all  production
into the Macungie, PA plant.

    Selling,  general  and administrative costs for  the  period  decreased
during  the three and six months ended June 30, 2003 when compared  to  the
same periods in 2002.

Other Income and Expense
    Investment income decreased during the three and six months ended  June
30,  2003  when compared to the same periods in 2002 due to lower rates  of
return available on invested funds.

Income Taxes
    The tax provision for the three and six months ended June 30, 2003  are
based on the estimated effective tax rate for the year, which is less  than
the statutory rate due to tax credits and exempt income.

Factors that May Affect Operating Results
   The statements contained in this report on Form 10-Q that are not purely
historical are forward looking statements within the meaning of Section 27A
of  the  Securities Act of 1933 and Section 21E of the Securities  Exchange
Act  of  1934,  including statements regarding the Company's  expectations,
hopes,  intentions  or  strategies regarding the future.   Forward  looking
statements  include:  statements  regarding  future  products  or   product
development; statements regarding future research and development  spending
and  the  Company's marketing and product development strategy,  statements
regarding  future  production  capacity.  All  forward  looking  statements
included in this document are based on information available to the Company
on  the  date hereof, and the Company assumes no obligation to  update  any
such  forward looking statements.  Readers are cautioned not to place undue
reliance  on  these forward looking statements, which reflect  management's
opinions  only as of the date hereof.  Readers should carefully review  the
risk  factors described in other documents the Company files from  time  to
time  with  the  Securities and Exchange Commission, including  the  Annual
Report  on  Form  10-K.  It is important to note that the Company's  actual
results  could  differ  materially  from  those  in  such  forward  looking
statements.  Some of the factors that could cause actual results to  differ
materially are set forth below.

   The  Company  has  experienced and expects  to  continue  to  experience
fluctuations  in  its  results  of operations.   Factors  that  affect  the
Company's  results of operations include the volume and  timing  of  orders
received, changes in global economics and financial markets, changes in the
mix of products sold, market acceptance of the Company's and its customer's
products,  competitive pricing pressures, global currency  valuations,  the
availability  of  electronic  components that the  Company  purchases  from
suppliers,  the Company's ability to meet increasing demand, the  Company's
ability  to  introduce new products on a timely basis, the  timing  of  new
product  announcements and introductions by the Company or its competitors,
changing  customer requirements, delays in new product qualifications,  the
timing and extent of research and development expenses and fluctuations  in
manufacturing yields.  As a result of the foregoing or other factors, there
can  be  no  assurance  that  the  Company  will  not  experience  material
fluctuations  in future operating results on a quarterly or  annual  basis,
which  would  materially  and  adversely  affect  the  Company's  business,
financial condition and results of operations.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
   No change from information disclosed in the Company's 2002 annual
   report on Form 10-K.

ITEM 4.  CONTROLS AND PROCEDURES.
   Within ninety days prior to the filing of this Report, the Company's
   Chief Executive Officer and Chief Financial Officer evaluated the
   effectiveness of the design and operation of the Company's disclosure
   controls and procedures, which are designed to insure that the Company
   records, processes, summarizes and reports in a timely and effective
   manner the information required to be disclosed in the reports filed
   with or submitted to the Securities and Exchange Commission.  Based
   upon this evaluation, they concluded that, as of the date of the
   evaluation, the Company's disclosure controls are effective.  Since the
   date of this evaluation, there have been no significant changes in the
   Company's internal controls or in other factors that could
   significantly affect those controls.

PART II    OTHER INFORMATION
   Item 4.     Submission of Matters to a Vote of Security Holders
   (a)       Annual Meeting: April 24, 2003
   (b)        Election  of the following directors for a one-year  term:
        Steven   Markowitz,  Eugene  Moroz,  Leonard  Helfrich,   Martha
        Markowitz,  Orville  Hawk,  Albert Schuster,  Jeffrey  Schucker,
        Ernest Choquette and Michael Doyle.
   (c)        In addition to the election of directors and the waiver of
        reading  of  the minutes of the prior meeting, the  shareholders
        ratified  charitable deductions made in 2002 and all  contracts,
        agreements,  and  employments by  the  Board  of  Directors  and
        officers  since the previous annual meeting in April 2002.   All
        resolutions  were  adopted  by  the  vote  of  all  shareholders
        present, in person or proxy.
   Item 6.     Exhibits and Reports on Form 8-K
   (a)  Exhibits
        Exhibit No.            Description
         31.1      Rule 13a-14(a)/15d-14(a) Certification - Chief Executive
                   Officer
         31.2      Rule 13a-14(a)/15d-14(a) Certification - Chief Financial
                   Officer
         32        Section 1350 Certifications
   (b)  No reports on Form 8-K were filed during the quarter ended June 30,
      2003.
<PAGE>

SIGNATURES
Pursuant  to the requirements of the Securities Exchange Act of  1934,  the
registrant  has duly caused this report to be signed on its behalf  by  the
undersigned thereunto duly authorized.
                                       Allen Organ Company
                                         (Registrant)

Date: August 13, 2003       /s/STEVEN MARKOWITZ
                            Steven Markowitz, President and Chief
                            Executive Officer


Date: August 13, 2003       /s/NATHAN S. ECKHART
                            Nathan S. Eckhart, Vice President-Finance,
                            Chief Financial and Principal Accounting Officer